FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint

KYNTRA BIO, INC.

Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.
Secondary endpoint (disease progression or death) also not met (HR=0.78, 95% CI 0.52-1.15).
ZEPHYRUS-2 Phase 3 IPF trial will be discontinued based on these results.
Company plans cost reductions to extend cash runway into 2026; roxadustat commercialization continues.
Upcoming milestones: DMD data 3Q 2023, pancreatic cancer data 1H 2024, new IND filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.